Ver­tex wins third CF ap­proval in Eu­rope; ERS Ge­nomics grants Defini­GEN ac­cess to CRISPR/Cas9 tech

→ Ver­tex $VRTX has scored its third cys­tic fi­bro­sis treat­ment ap­proval, with the Eu­ro­pean Com­mis­sion giv­ing Symke­vi (teza­caftor/iva­caftor) in com­bi­na­tion with Ka­ly­de­co (iva­caftor) the nod for CF pa­tients with cer­tain mu­ta­tions in the CFTR gene. The treat­ment is al­ready ap­proved the US and Cana­da and is aimed at pa­tients with resid­ual func­tion mu­ta­tions and those who can­not tol­er­ate Orkam­bi (lumacaftor/iva­caftor).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER